For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com.
Lexicon is a biopharmaceutical company focused on the discovery and
development of breakthrough treatments for human disease. Lexicon currently
has development programs underway for such areas of major unmet medical
need as irritable bowel syndrome, cognitive disorders, autoimmune diseases,
and carcinoid syndrome. The company has used its proprietary gene knockout
technology to discover more than 100 promising drug targets and create an
extensive pipeline of clinical and preclinical programs in the therapeutic
areas of cardiology, gastroenterology, immunology and oncology, metabolism,
neurology and ophthalmology. To advance the development and
commercialization of its programs, Lexicon is working both independently
and through collaborators including Bristol-Myers Squibb Co., Genentech,
Inc. and N.V. Organon. For additional information about Lexicon and its
programs, please visit http://www.lexpharma.com.
For further information please contact:
Danish media International media
Alex Haahr Gouliaev, CEO Chris Gardner/Mark Swallow
Phone: +45-7020-0987 Phone: +44(0)207-282-2995/+44(0)207-282-2948
Lexicon Pharmaceuticals, Inc.
Stephen Tragash, Executive Director, Corporate Affairs
|SOURCE Nuevolution A/S|
Copyright©2008 PR Newswire.
All rights reserved